Merrill Lynch UK Inv Tst PLC
12 September 2001
MONTHLY PERFORMANCE
MERRILL LYNCH UK INVESTMENT TRUST plc
All information is at 31 August 2001 and unaudited.
Performance at month end with net income reinvested
One Three One Three Five
month months year years years
Net asset value -2.0% -9.9% -22.9% 0.8% 35.3%
Share price -2.6% -12.6% -16.9% -6.5% 20.5%
FTSE All-Share Index -2.3% -7.2% -17.3% 14.0% 54.0%
Sources: Merrill Lynch Investment Managers, Standard & Poor's Micropal
At month end
Net asset value* 995.42p
Share price: 892.50p
Discount: 10.3%
Total assets: £178.7m
Net Yield: 3.4%
Gearing: 28.3%
Effective gearing: 28.1%
Value of debt: £39.5m
Ordinary shares in issue: 14,093,562
(There were no share repurchases during the month)
*Includes current year net revenue of 7.70p.
UK Sectors % Portfolio
Financials 23.9
Cyclical Services 22.3
Non-Cyclical Consumer Goods 16.2
Resources 15.0
Non-Cyclical Services 10.3
Basic Industries 6.5
Utilities 3.2
General Industrials 3.1
Information Technology 0.1
Net current liabilities (0.6)
Total 100.0
Ten Largest Equity Investments
Company
% Investments
BP Amoco 8.8
Royal Bank of Scotland 6.3
GlaxoSmithKline 6.2
Barclays 5.5
Vodafone 5.2
AstraZeneca 5.1
British Telecom 2.9
Shell Transport and Trading Co 2.7
Tesco 2.1
International Power 2.1
Total 46.9
Update commentary
UK Stockmarket Review
The FTSE All Share Index slipped by a further 2.3% in August. Concerns that US
consumer confidence may be faltering and further negative corporate earnings
news flow prompted more selling, despite interest rate cuts and some more
encouraging economic news. Sentiment continues to rotate between fear and hope
as investors contrast the poor immediate term earnings environment with
expectations that global economic conditions are likely to improve as we enter
2002.
Fund Performance Review
The Net Asset Value (NAV) of Merrill Lynch UK Investment Trust plc
outperformed on a relative basis during August, falling by 2.0%.
MLIM's UK Specialist Equity Team maintain a slight defensive tilt in their
portfolios, while adding to cyclical exposure as valuations warrant. The Trust
is well represented in UK consumer demand-orientated businesses, such as
retailers and construction companies. This stance aided relative performance
in August.
AMEC and Balfour Beatty performed well, after suffering in July as a result of
adverse press concerning PFI and news of Laing's additional provisioning. We
had complemented our overweight position in building & construction companies
by adding to Hanson. This share and our other holdings in this area performed
strongly.
We were well represented in typically defensive sectors, such as
pharmaceuticals. Our favour for AstraZeneca over GlaxoSmithKline aided
relative performance, although it was our long held position in Amersham that
made the strongest contribution.
Our choice of shares within growth areas was beneficial. We maintained a focus
on large, relatively well funded telecoms companies, which aided relative
performance, while some previously de-rated holdings within media rose
strongly during the month. The Trust remains very lightly represented in
technology companies and exposure to the alternative telecoms carriers has
been reduced significantly.
Outlook
In the UK, unemployment remains low, house prices are firm and household
income growth is meaningful. This suggests to us that retail sales should
remain supported. As such, we expect the UK stockmarket to prove relatively
resilient in the face of continued pressure on corporate earnings in the US
and continental Europe. Our cyclical exposure is likely to be enhanced further
if signs of economic recovery reinforce our conviction regarding the prospects
for economic upturn into 2002.
Latest information is available by typing www.mlim.co.uk/its on the internet,
'MLIMINDEX' on Reuters, 'MLIM' on Bloomberg or '8800' on Topic 3 (ICV
terminal).
12 September 2001
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.